Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Osteo Arthritis Knee
Interventions: Ipack, Bupivacaine, Peri Articular Infiltration; Device · Drug · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Use Disorder (AUD)
Interventions: TMP-301, Placebo; Drug
Lead sponsor: Tempero Bio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Hollywood, Florida + 11 more

Conditions: Glaucoma
Interventions: Ahmed implant, Baerveldt implant; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteoarthritis
Interventions: Ensure; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Polymyositis, Dermatomyositis
Interventions: Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label); Combination Product · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 43
States / cities: Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more

Conditions: Asthma in Children
Interventions: CASE Program, HARP Program; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 2 Years to 12 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma
Interventions: tafasitamab, rituximab, lenalidomide, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 38
States / cities: Concord, California • Greenbrae, California • Pasadena, California + 33 more

Conditions: Conduct Disorder, Anti-Social Behavior
Interventions: Fast Track; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 6 Years to 8 Years
Enrollment: 891 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 38
States / cities: Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more

Conditions: Tendonitis;Achilles
Interventions: Micronized DHACM, Saline Injection; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Carlsbad, California + 10 more

Conditions: Acne Vulgaris
Interventions: GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 34
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more

Conditions: Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions: Sugammadex, Neostigmine; Drug
Lead sponsor: Virtua Health, Inc.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Mount Holly, New Jersey

Conditions: Cocaine Dependence
Interventions: cocaine hydrochloride, exenatide, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Occupational Injuries, Occupational Exposure
Interventions: Intelligent Physical Exercise Training (IPET); Behavioral
Lead sponsor: University of Aarhus; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Rochester, Minnesota

Conditions: Contraception, Prevention of Sexually Transmitted Infections
Interventions: Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B; Device
Lead sponsor: Sagami Rubber Industries Co., Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV-1 Infections
Interventions: dapivirine 4789, dapivirine gel 4759, Drug placebo; Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more

Conditions: Cerebrospinal Fluid Leakage, Subdural
Interventions: Spinal Sealant, Standard of Care; Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Pre-diabetes, Metabolic Syndrome
Interventions: Active, Control; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 25 Years to 60 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: ADT Order Check Attestation (Or), Provider Script (Sc); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opioid Use, Unspecified
Interventions: Ropivacaine, Dexmedetomidine, Dexamethasone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Achondroplasia
Interventions: Navepegritide, Placebo for Navepegritide; Drug
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 0 Years to 2 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: VNX001, Placebo, Lidocaine, Heparin; Drug
Lead sponsor: Vaneltix Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Escondido, California • Los Angeles, California • Newport Beach, California + 10 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 113
States / cities: Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more

Conditions: Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more

Search by objective public record fields.

Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty

A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder

Ahmed Versus Baerveldt Comparison Study

Oral Nutritional Optimization in Total Joint Arthroplasty

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Rhode Island Asthma Integrated Response Program

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Multisite Prevention of Conduct Problems (Fast Track)

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Micronized dHACM Injectable for the Treatment of Achille Tendonitis

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

The Effect of Intelligent Exercise and Ergonomic Recommendations on Surgeon Musculoskeletal Discomfort

Evaluation of Polyurethane Male Condoms

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

Study to Evaluate Safety & Effectiveness of Spinal Sealant

Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers

DeADT - Living Well With Prostate Cancer

the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS